← Leaderboards
Leonid B Heifets
National Jewish Health
$710,915
Attributed
$710,915
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$785,410 · 3
By mechanism
R21$710,915 · 2
U19$74,495 · 1
Top collaborators
No co-investigators on record.
Most similar at National Jewish Health
Same institution · by research overlap
- Edward D Chan$2,011,232
- Karina Serban$2,991,972
- Willi K Born$4,873,117
- Peter M Henson$23,575,855
- Russell Paul Bowler$12,856,977
Others in their field
Top investigators on “Antitubercular Agents”
- David Alland · Rutgers Biomedical And Health Sciences$14,918,108
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$13,387,732
- Mina C Hosseinipour · Univ Of North Carolina Chapel Hill$13,387,732
- John R. Chan · Rutgers Biomedical And Health Sciences$11,578,548
- Mark Fredric Cotton · Stellenbosch University$11,071,445
- Chinnaswamy Jagannath · University Of Texas Hlth Sci Ctr Houston$10,931,439
Research focus
Antitubercular AgentsMycobacterium TuberculosisMacrophageDrug Screening /EvaluationPharmacokineticsHuman TissueDrug Delivery SystemsBlood ProteinsHigh Performance Liquid ChromatographyImmunocytochemistryIntracellular TransportCell Surface ReceptorsLaboratory RabbitMannoseMicrocapsuleConfocal Scanning MicroscopyParticleNanotechnologyPolyethylene GlycolsTechnology /Technique DevelopmentTerminal Nick End LabelingBioaccumulationTransferrinTuberculosis
Grant awards (4)
Nanoparticle delivery system for antiturberculosis drug$227,400
R21 · FY2004 · AI
Nanoparticle delivery system for antiturberculosis drug$222,615
R21 · FY2003 · AI
NEW CLASS OF ANTITUBERCULOSIS AMIDES:PRECLINICAL DEVELOP$260,900
R21 · FY2001 · AI
PRECLINICAL DEVELOPMENT OF NEW ANTITUBERCULOSIS REGIMEN$74,495
U19 · FY2000 · AI